$ENZN
Enzon Pharmaceuticals Inc Stock $enzn

$enzn Overview Financials Valuation SEC Filings Company Website

2014 Q4 Form 10-Q Financial Statement

#000114420414065728 Filed on November 06, 2014

Income Statement

Concept	2014 Q4	2014 Q3	2013 Q3
Revenue	$6.270M	$8.164M	$8.828M
YoY Change	-15.57%	-7.52%	-20.62%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$470.0K	$570.0K	$2.260M
YoY Change	-62.1%	-74.78%	-29.6%
% of Gross Profit
Research & Development	$0.00	$0.00	$653.0K
YoY Change	-100.0%	-100.0%	-83.49%
% of Gross Profit
Depreciation & Amortization	$0.00	$0.00	$0.00
YoY Change			-100.0%
% of Gross Profit
Operating Expenses	$470.0K	$571.0K	$3.706M
YoY Change	-67.13%	-84.59%	-47.51%
Operating Profit		$7.593M	$5.122M
YoY Change		48.24%	26.13%
Interest Expense	$0.00	$0.00	$0.00
YoY Change			-100.0%
% of Operating Profit		0.0%	0.0%
Other Income/Expense, Net		$0.00	$195.0K
YoY Change		-100.0%	9650.0%
Pretax Income	$5.800M	$7.593M	$5.321M
YoY Change	5.84%	42.7%	27.45%
Income Tax	$0.00	$1.000K	-$241.0K
% Of Pretax Income	0.0%	0.01%	-4.53%
Net Earnings	$5.800M	$7.592M	$5.562M
YoY Change	5.86%	36.5%	33.22%
Net Earnings / Revenue	92.5%	92.99%	63.0%
Basic Earnings Per Share		$0.17	$0.13
Diluted Earnings Per Share	$131.2K	$0.17	$0.13
COMMON SHARES
Basic Shares Outstanding	44.14M shares	44.13M shares	43.92K shares
Diluted Shares Outstanding		44.24M shares	44.14M shares

Balance Sheet

Concept	2014 Q4	2014 Q3	2013 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$34.60M	$29.00M	$21.70M
YoY Change	432.31%	33.64%	-92.21%
Cash & Equivalents	$34.56M	$28.99M	$21.69M
Short-Term Investments			$0.00
Other Short-Term Assets	$478.0K	$329.0K	$1.200M
YoY Change	-6.46%	-72.58%	-45.45%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$35.04M	$29.30M	$22.90M
YoY Change	392.07%	27.95%	-91.84%
LONG-TERM ASSETS
Property, Plant & Equipment			$0.00
YoY Change			-100.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$0.00	$22.00K	$0.00
YoY Change			-100.0%
TOTAL ASSETS
Total Short-Term Assets	$35.04M	$29.30M	$22.90M
Total Long-Term Assets	$0.00	$22.00K	$0.00
Total Assets	$35.04M	$29.32M	$22.90M
YoY Change	392.07%	28.04%	-92.48%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$181.0K	$151.0K	$200.0K
YoY Change	94.62%	-24.5%	-81.82%
Accrued Expenses	$458.0K	$529.0K	$2.300M
YoY Change	-62.3%	-77.0%	-68.92%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$5.056M	$680.0K	$2.500M
YoY Change	286.54%	-72.8%	-97.99%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$400.0K	$400.0K	$600.0K
YoY Change	-33.33%	-33.33%	20.0%
Total Long-Term Liabilities	$400.0K	$400.0K	$600.0K
YoY Change	-33.33%	-33.33%	20.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$5.056M	$680.0K	$2.500M
Total Long-Term Liabilities	$400.0K	$400.0K	$600.0K
Total Liabilities	$5.437M	$1.102M	$3.100M
YoY Change	191.37%	-64.45%	-97.52%
SHAREHOLDERS EQUITY
Retained Earnings	-$100.9M	-$106.7M
YoY Change	-22.2%
Common Stock	$130.5M	$134.9M
YoY Change	-3.3%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$29.60M	$28.22M	$19.80M
YoY Change
Total Liabilities & Shareholders Equity	$35.04M	$29.32M	$22.90M
YoY Change	392.07%	28.04%	-92.48%

Cashflow Statement

Concept	2014 Q4	2014 Q3	2013 Q3
OPERATING ACTIVITIES
Net Income	$5.800M	$7.592M	$5.562M
YoY Change	5.86%	36.5%	33.22%
Depreciation, Depletion And Amortization	$0.00	$0.00	$0.00
YoY Change			-100.0%
Cash From Operating Activities	$9.900M	$7.600M	$6.900M
YoY Change	153.85%	10.14%	25.45%
INVESTING ACTIVITIES
Capital Expenditures			$0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities	$0.00	$0.00	$3.500M
YoY Change	-100.0%	-100.0%	-96.2%
Cash From Investing Activities	$0.00	$0.00	$3.500M
YoY Change	-100.0%	-100.0%	-96.2%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-4.400M	0.000	-100.0K
YoY Change	-77.89%	-100.0%	-99.38%
NET CHANGE
Cash From Operating Activities	9.900M	7.600M	6.900M
Cash From Investing Activities	0.000	0.000	3.500M
Cash From Financing Activities	-4.400M	0.000	-100.0K
Net Change In Cash	5.500M	7.600M	10.30M
YoY Change	-136.18%	-26.21%	-87.38%
FREE CASH FLOW
Cash From Operating Activities	$9.900M	$7.600M	$6.900M
Capital Expenditures			$0.00
Free Cash Flow			$6.900M
YoY Change			25.45%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2014Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-106703000	USD
CY2013Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-129698000	USD
CY2014Q3	us-gaap	Stockholders Equity StockholdersEquity	28220000	USD
CY2013Q4	us-gaap	Stockholders Equity StockholdersEquity	5255000	USD
	us-gaap	Use Of Estimates UseOfEstimates	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><i>Use of Estimates</i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify">The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the U.S. requires management to make estimates and assumptions that affect reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Although management bases its estimates on historical experience and various other assumptions that are believed to be reasonable under the circumstances, actual results could differ from these estimates.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2014Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	28993000	USD
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	6520000	USD
CY2014Q3	us-gaap	Other Assets Current OtherAssetsCurrent	329000	USD
CY2013Q4	us-gaap	Other Assets Current OtherAssetsCurrent	511000	USD
CY2014Q3	us-gaap	Assets Of Disposal Group Including Discontinued Operation Current AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent	0	USD
CY2013Q4	us-gaap	Assets Of Disposal Group Including Discontinued Operation Current AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent	90000	USD
CY2014Q3	us-gaap	Assets Assets	29322000	USD
CY2013Q4	us-gaap	Assets Assets	7121000	USD
CY2014Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	151000	USD
CY2013Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	93000	USD
CY2014Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	529000	USD
CY2013Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1215000	USD
CY2014Q3	us-gaap	Liabilities Current LiabilitiesCurrent	680000	USD
CY2013Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1308000	USD
CY2014Q3	us-gaap	Accrued Rent Noncurrent AccruedRentNoncurrent	422000	USD
CY2013Q4	us-gaap	Accrued Rent Noncurrent AccruedRentNoncurrent	558000	USD
CY2014Q3	us-gaap	Liabilities Liabilities	1102000	USD
CY2013Q4	us-gaap	Liabilities Liabilities	1866000	USD
CY2014Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2013Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2014Q3	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2013Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2014Q3	us-gaap	Common Stock Value CommonStockValue	441000	USD
CY2013Q4	us-gaap	Common Stock Value CommonStockValue	441000	USD
CY2014Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	134482000	USD
CY2013Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	134512000	USD
CY2014Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	29322000	USD
CY2013Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	7121000	USD
CY2013Q3	us-gaap	Area Of Land AreaOfLand	30000	sqft
CY2013Q3	enzn	Monthly Fixed Rent Receivable On Sublease Year One MonthlyFixedRentReceivableOnSubleaseYearOne	10417	USD
CY2013Q3	enzn	Monthly Fixed Rent Receivable On Sublease Year Two MonthlyFixedRentReceivableOnSubleaseYearTwo	15625	USD
CY2013Q3	enzn	Monthly Fixed Rent Receivable On Sublease Year Three MonthlyFixedRentReceivableOnSubleaseYearThree	20833	USD
CY2013Q3	enzn	Monthly Fixed Rent Receivable On Sublease Year Four MonthlyFixedRentReceivableOnSubleaseYearFour	26042	USD
CY2013Q3	enzn	Monthly Fixed Rent Receivable On Sublease In Each Of Year Five To Eight MonthlyFixedRentReceivableOnSubleaseInEachOfYearFiveToEight	35000	USD
CY2013	enzn	Royalty Revenues From Sales Percentage RoyaltyRevenuesFromSalesPercentage	0.87	pure
	enzn	Royalty Revenues From Sales Percentage RoyaltyRevenuesFromSalesPercentage	0.79	pure
CY2013Q3	enzn	Royalty Revenues From Sales Percentage RoyaltyRevenuesFromSalesPercentage	0.91	pure
CY2014Q3	enzn	Royalty Revenues From Sales Percentage RoyaltyRevenuesFromSalesPercentage	0.77	pure
CY2013Q3	enzn	Sub Lease Commencement Date SubLeaseCommencementDate	2013-11-14
CY2013Q3	enzn	Sublease Expiration Date SubleaseExpirationDate	2021-07-30
CY2014Q1	enzn	Reduction In General And Administrative Expense ReductionInGeneralAndAdministrativeExpense	300435	USD
	us-gaap	Available For Sale Securities Gross Realized Gains Losses Sale Proceeds AvailableForSaleSecuritiesGrossRealizedGainsLossesSaleProceeds	300000	USD
CY2013Q3	us-gaap	Available For Sale Securities Gross Realized Gains Losses Sale Proceeds AvailableForSaleSecuritiesGrossRealizedGainsLossesSaleProceeds	39000	USD
CY2010Q4	us-gaap	Stock Repurchase Program Authorized Amount1 StockRepurchaseProgramAuthorizedAmount1	200000000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	12671000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	22995000	USD
CY2013Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	5562000	USD
CY2014Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	7592000	USD
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	43782000	shares
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.29
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.52
CY2013Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.13
CY2014Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.17
CY2013Q3	us-gaap	Net Income Loss NetIncomeLoss	5562000	USD
CY2014Q3	us-gaap	Net Income Loss NetIncomeLoss	7592000	USD
	us-gaap	Interest On Convertible Debt Net Of Tax InterestOnConvertibleDebtNetOfTax	1142000	USD
	us-gaap	Interest On Convertible Debt Net Of Tax InterestOnConvertibleDebtNetOfTax	0	USD
CY2013Q3	us-gaap	Interest On Convertible Debt Net Of Tax InterestOnConvertibleDebtNetOfTax	0	USD
CY2014Q3	us-gaap	Interest On Convertible Debt Net Of Tax InterestOnConvertibleDebtNetOfTax	0	USD
	us-gaap	Net Income Loss Attributable To Parent Diluted NetIncomeLossAttributableToParentDiluted	13813000	USD
	us-gaap	Net Income Loss Attributable To Parent Diluted NetIncomeLossAttributableToParentDiluted	22995000	USD
CY2013Q3	us-gaap	Net Income Loss Attributable To Parent Diluted NetIncomeLossAttributableToParentDiluted	5562000	USD
CY2014Q3	us-gaap	Net Income Loss Attributable To Parent Diluted NetIncomeLossAttributableToParentDiluted	7592000	USD
	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	172000	shares
	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	145000	shares
CY2013Q3	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	216000	shares
CY2014Q3	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	108000	shares
	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities	9514000	shares
	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities	0	shares
CY2013Q3	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities	0	shares
CY2014Q3	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities	0	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	53468000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	44254000	shares
CY2013Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	44137000	shares
CY2014Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	44239000	shares
	enzn	Sub Lease Commencement Date SubLeaseCommencementDate	2013-11-14
	enzn	Sublease Expiration Date SubleaseExpirationDate	2021-07-30
CY2014Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2013Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2014Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	3000000	shares
CY2013Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	3000000	shares
CY2014Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2014Q3	us-gaap	Area Of Land AreaOfLand	30000	sqft
CY2014Q3	enzn	Monthly Fixed Rent Receivable On Sublease Year One MonthlyFixedRentReceivableOnSubleaseYearOne	10417	USD
CY2014Q3	enzn	Monthly Fixed Rent Receivable On Sublease Year Two MonthlyFixedRentReceivableOnSubleaseYearTwo	15625	USD
CY2014Q3	enzn	Monthly Fixed Rent Receivable On Sublease Year Three MonthlyFixedRentReceivableOnSubleaseYearThree	20833	USD
CY2014Q3	enzn	Monthly Fixed Rent Receivable On Sublease In Each Of Year Five To Eight MonthlyFixedRentReceivableOnSubleaseInEachOfYearFiveToEight	35000	USD
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.26
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.52
CY2013Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.13
CY2013Q1	us-gaap	Restructuring Charges RestructuringCharges	2500000	USD
CY2013Q2	us-gaap	Restructuring Charges RestructuringCharges	596000	USD
CY2013Q3	us-gaap	Restructuring Charges RestructuringCharges	794000	USD
CY2013Q1	us-gaap	Payments For Restructuring PaymentsForRestructuring	1600000	USD
	us-gaap	Payments For Restructuring PaymentsForRestructuring	479000	USD
CY2013Q2	us-gaap	Payments For Restructuring PaymentsForRestructuring	501000	USD
CY2014Q3	us-gaap	Restructuring Reserve RestructuringReserve	425000	USD
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2125000	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0	shares
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	321000	shares
CY2014Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1804000	shares
CY2014Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	1804000	shares
CY2014Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	1737000	shares
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	166000	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	0	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod	89000	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod	0	shares
CY2014Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	77000	shares
	enzn	Employee Service Share Based Compensation Tax Payments EmployeeServiceShareBasedCompensationTaxPayments	300000	USD
CY2013Q3	enzn	Employee Service Share Based Compensation Tax Payments EmployeeServiceShareBasedCompensationTaxPayments	100000	USD
	enzn	Adjustment To Additional Paid In Capital Income Tax Effect From Share Based Compensation AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensation	300000	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	156000	shares
	enzn	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue	200000	USD
	us-gaap	Common Stock Dividends Per Share Cash Paid CommonStockDividendsPerShareCashPaid	1.60
CY2013	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4000	USD
CY2014Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1000	USD
CY2013Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2014Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2013Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2014Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2013Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2014Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	170000000	shares
CY2013Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	170000000	shares
CY2014Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	44142340	shares
CY2013Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	44085870	shares
CY2014Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	44142340	shares
CY2013Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	44085870	shares
	us-gaap	Royalty Revenue RoyaltyRevenue	26436000	USD
	us-gaap	Royalty Revenue RoyaltyRevenue	24811000	USD
CY2013Q3	us-gaap	Royalty Revenue RoyaltyRevenue	8828000	USD
CY2014Q3	us-gaap	Royalty Revenue RoyaltyRevenue	8133000	USD
	us-gaap	Other Sales Revenue Net OtherSalesRevenueNet	631000	USD
	us-gaap	Other Sales Revenue Net OtherSalesRevenueNet	94000	USD
CY2013Q3	us-gaap	Other Sales Revenue Net OtherSalesRevenueNet	0	USD
CY2014Q3	us-gaap	Other Sales Revenue Net OtherSalesRevenueNet	31000	USD
	us-gaap	Sales Revenue Net SalesRevenueNet	27067000	USD
	us-gaap	Sales Revenue Net SalesRevenueNet	24905000	USD
CY2013Q3	us-gaap	Sales Revenue Net SalesRevenueNet	8828000	USD
CY2014Q3	us-gaap	Sales Revenue Net SalesRevenueNet	8164000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2525000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	0	USD
CY2013Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	653000	USD
CY2014Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	0	USD
	us-gaap	Other General And Administrative Expense OtherGeneralAndAdministrativeExpense	7606000	USD
	us-gaap	Other General And Administrative Expense OtherGeneralAndAdministrativeExpense	1915000	USD
CY2013Q3	us-gaap	Other General And Administrative Expense OtherGeneralAndAdministrativeExpense	2259000	USD
CY2014Q3	us-gaap	Other General And Administrative Expense OtherGeneralAndAdministrativeExpense	571000	USD
	us-gaap	Restructuring Charges RestructuringCharges	3764000	USD
	us-gaap	Restructuring Charges RestructuringCharges	0	USD
CY2014Q3	us-gaap	Restructuring Charges RestructuringCharges	0	USD
	us-gaap	Operating Expenses OperatingExpenses	13895000	USD
	us-gaap	Operating Expenses OperatingExpenses	1915000	USD
CY2013Q3	us-gaap	Operating Expenses OperatingExpenses	3706000	USD
CY2014Q3	us-gaap	Operating Expenses OperatingExpenses	571000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	13172000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	22990000	USD
CY2013Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	5122000	USD
CY2014Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	7593000	USD
	us-gaap	Investment Income Net InvestmentIncomeNet	534000	USD
	us-gaap	Investment Income Net InvestmentIncomeNet	0	USD
CY2013Q3	us-gaap	Investment Income Net InvestmentIncomeNet	4000	USD
CY2014Q3	us-gaap	Investment Income Net InvestmentIncomeNet	0	USD
	us-gaap	Interest Expense InterestExpense	2124000	USD
	us-gaap	Interest Expense InterestExpense	0	USD
CY2013Q3	us-gaap	Interest Expense InterestExpense	0	USD
CY2014Q3	us-gaap	Interest Expense InterestExpense	0	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1061000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	61000	USD
CY2013Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	195000	USD
CY2014Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	0	USD
	enzn	Non Operating Income Expense Including Interest Expense NonOperatingIncomeExpenseIncludingInterestExpense	-529000	USD
	enzn	Non Operating Income Expense Including Interest Expense NonOperatingIncomeExpenseIncludingInterestExpense	61000	USD
CY2013Q3	enzn	Non Operating Income Expense Including Interest Expense NonOperatingIncomeExpenseIncludingInterestExpense	199000	USD
CY2014Q3	enzn	Non Operating Income Expense Including Interest Expense NonOperatingIncomeExpenseIncludingInterestExpense	0	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	12643000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	23051000	USD
CY2013Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	5321000	USD
CY2014Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	7593000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-28000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	56000	USD
CY2013Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-241000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	238000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	0	USD
CY2013Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	4000	USD
CY2014Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	0	USD
	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax	320000	USD
	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax	0	USD
CY2013Q3	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax	0	USD
CY2014Q3	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax	0	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-82000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	0	USD
CY2013Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	4000	USD
CY2014Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	0	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	12589000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	22995000	USD
CY2013Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	5566000	USD
CY2014Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	7592000	USD
	us-gaap	Common Stock Dividends Per Share Cash Paid CommonStockDividendsPerShareCashPaid	0
CY2013Q3	us-gaap	Common Stock Dividends Per Share Cash Paid CommonStockDividendsPerShareCashPaid	0
CY2014Q3	us-gaap	Common Stock Dividends Per Share Cash Paid CommonStockDividendsPerShareCashPaid	0
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	218000	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	0	USD
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	193000	USD
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	0	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	-54000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	0	USD
	us-gaap	Marketable Securities Gain Loss MarketableSecuritiesGainLoss	320000	USD
	us-gaap	Marketable Securities Gain Loss MarketableSecuritiesGainLoss	0	USD
	enzn	Amortization Of Purchase Premium On Marketable Securities AmortizationOfPurchasePremiumOnMarketableSecurities	735000	USD
	enzn	Amortization Of Purchase Premium On Marketable Securities AmortizationOfPurchasePremiumOnMarketableSecurities	0	USD
	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	1060000	USD
	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	61000	USD
	us-gaap	Increase Decrease In Operating Capital IncreaseDecreaseInOperatingCapital	2276000	USD
	us-gaap	Increase Decrease In Operating Capital IncreaseDecreaseInOperatingCapital	583000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	10107000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	22351000	USD
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	1451000	USD
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	152000	USD
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	118894000	USD
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	0	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	120345000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	152000	USD
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	269000	USD
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	30000	USD
	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	-33000	USD
	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	0	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	-186109000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	-30000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-55657000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	22473000	USD
CY2012Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	77348000	USD
CY2013Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	21691000	USD
	us-gaap	Nature Of Operations NatureOfOperations	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"> <table style="LINE-HEIGHT: 115%; WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="1%"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt">  </div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="3%"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt"> <b><font style="FONT-SIZE: 10pt">(1)</font></b></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 96%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="96%"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><b><font style="FONT-SIZE: 10pt">Description of Business</font></b></div> </td> </tr> </table> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt 36.75pt; size: 8.5in 11.0in" align="justify"><b> </b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"> Enzon Pharmaceuticals, Inc. (together with its subsidiaries, “Enzon” or the “Company”) receives royalty revenues from existing licensing arrangements with other companies primarily related to sales of six marketed drug products, namely, PegIntron <sup style="font-style:normal">®</sup> , Sylatron <sup style="font-style:normal">®</sup> , Macugen <sup style="font-style:normal">®</sup> , CIMZIA <sup style="font-style:normal">®</sup> , Oncaspar and Adagen. The primary source of the Company’s royalty revenues is sales of PegIntron, which is marketed by Merck & Co., Inc. (“Merck”). The Company currently has no clinical operations and limited corporate operations. The Company operates in one business segment. Royalty revenues from sales of PegIntron accounted for approximately 77% and 91% of our total royalty revenues for the three months ended September 30, 2014 and 2013, respectively, and approximately 79% and 89% of the Company’s total royalty revenues in the nine months ended September 30, 2014 and 2013, respectively. Royalty revenues from sales of PegIntron accounted for approximately 87%, 93% and 94% of our total royalty revenues in 2013, 2012 and 2011.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify">The Company was previously dedicated to the research and development of innovative therapeutics for patients with high unmet medical needs.   In December 2012, the Company announced that the Company’s Board of Directors (the “Board”) retained Lazard Frères & Co. LLC (“Lazard”) to act as financial advisor in a review of the possible sale or disposition of one or more corporate assets or a sale of the Company and that the Company’s Board of Directors established a special committee to oversee the Company’s sale review process. In connection with the Company’s sale review process, the Company substantially suspended all clinical development activities with a goal of conserving capital and maximizing value returned to the Company’s stockholders.   In April 2013, the Company announced that it had concluded a review of the sale or disposition of one or more corporate assets, or a sale of the Company.   The review did not result in a definitive offer to acquire the Company or all or substantially all of the Company’s assets.   In the same announcement, the Company also announced that its Board intends to distribute excess cash, expected to arise from ongoing royalty revenues, in the form of periodic dividends to stockholders.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify">In April 2013, pursuant to the terms of an asset purchase agreement, the Company sold to Belrose Pharma, Inc. (“Belrose”), all right, title and interest to the Company’s Customized PEGylation platform and related assets. The assets included (i) intellectual property and know-how associated with the PEGylation platform, (ii) patents and know-how related to PEG- SN-38, (iii) patents and know-how associated with certain of the Company’s internal clinical programs and (iv) certain related supplies and equipment.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify">In September 2013, the Company entered into a sublease agreement, which was amended and restated in November 2013, with Axcellerate Pharma, LLC (“Axcellerate”), pursuant to which the Company subleases to Axcellerate a portion of the Company’s premises consisting of approximately 30,000 rentable square feet of the building located at 20 Kingsbridge Road, Piscataway, New Jersey and a share of related parking areas. The term of the sublease commenced on November 14, 2013 and will expire on July 30, 2021. The monthly fixed rent payable by Axcellerate to us under the sublease is as follows: (i) in year one, $10,417, (ii) in year two, $15,625, (iii) in year three, $20,833, (iv) in year four, $26,042 and (v) in each of years five through eight, $35,000. The sublease also provides for Axcellerate to pay additional rent to cover its applicable share of real estate taxes, operating expenses, sewer and gas usage, water usage, electricity usage and certain other charges incurred by Axcellerate.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify">In October 2013, the Company terminated its License and Collaboration Agreement with Santaris Pharma A/S (“Santaris”) whereby Enzon returned to Santaris the rights to molecules utilizing LNA technology including the mRNA antagonists targeting Hypoxia-Inducible Factor-1 alpha (HIF-1 alpha), the Androgen Receptor (AR), HER3, and Beta-catenin.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify">In March 2014, the Company entered into a novation agreement with Zhejiang Hisun Pharmaceutical Co., Ltd. ("Hisun") and Belrose (the “Novation Agreement”), pursuant to which the parties confirmed the novation of the Company’s Collaboration Agreement with Hisun to Belrose. As a consequence of entering into the Novation Agreement, the Company received a gross amount of $550,000 from Hisun, the amount of a receivable previously written off, and paid $249,565 to Belrose. The recording of these transactions resulted in a net reduction of general and administrative expense of $300,435.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN-LEFT: 0in; size: 8.5in 11.0in" align="left">In March 2014, the Company entered into a novation agreement with Zhejiang Hisun Pharmaceutical Co., Ltd. ("Hisun") and Belrose (the “Novation Agreement”), pursuant to which the parties confirmed the novation of the Company’s Collaboration Agreement with Hisun to Belrose. As a consequence of entering into the Novation Agreement, the Company received a gross amount of $550,000 from Hisun, the amount of a receivable previously written off, and paid $249,565 to Belrose. The recording of these transactions resulted in a net reduction of general and administrative expense of $300,435.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN-LEFT: 0in; size: 8.5in 11.0in" align="left"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN-LEFT: 0in; size: 8.5in 11.0in" align="left">On July 16, 2014, Belrose provided written notice to Hisun asserting multiple breaches by Hisun of the Collaboration Agreement including failure to pay $450,000 of milestone payments. Belrose provided Hisun up to 60 days to cure the breaches. On September 16, Belrose notified Hisun and Enzon that it was terminating the Collaboration Agreement and demanded the return of material related to PEG-SN38 and a royalty-free right to any Hisun patents related to PEG-SN38. Hisun responded on September 16 that they rejected Belrose’s assertion that Hisun had committed multiple breaches and requested that Belrose continue its performance of technology transfer under the Collaboration Agreement. Enzon has received no further update on the status of this matter.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in"> The Company wound down its remaining research and development activities during 2013 and has no intention of resuming any clinical development activities or acquiring new sources of royalty revenues.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
	us-gaap	Basis Of Accounting BasisOfAccounting	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <table style="LINE-HEIGHT: 115%; WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="1%"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 10pt">  </div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="3%"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 10pt"> <b>(2)</b></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 96%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="96%"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 10pt" align="justify"><b>Basis of Presentation</b></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><i>Interim Financial Statements</i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify">The accompanying unaudited condensed consolidated financial statements have been prepared from the books and records of the Company in accordance with United States generally accepted accounting principles (U.S. GAAP) for interim financial information and Rule 10-01 of Regulation S-X promulgated by the U.S. Securities and Exchange Commission. Accordingly, these financial statements do not include all of the information and footnotes required for complete annual financial statements. Interim results are not necessarily indicative of the results that may be expected for the full year. Interim condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and the notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2013.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <i> </i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><i>Principles of Consolidation</i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify">The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated as part of the consolidation.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><i>Use of Estimates</i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify">The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the U.S. requires management to make estimates and assumptions that affect reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Although management bases its estimates on historical experience and various other assumptions that are believed to be reasonable under the circumstances, actual results could differ from these estimates.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
	us-gaap	Description Of New Accounting Pronouncements Not Yet Adopted DescriptionOfNewAccountingPronouncementsNotYetAdopted	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"> <table style="LINE-HEIGHT: 115%; WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="5%"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt"> <b><font style="FONT-SIZE: 6pt"> <font style="FONT-SIZE: 10pt">(3)</font></font></b></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 95%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="95%"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><b><font style="FONT-SIZE: 10pt">New Accounting Pronouncements</font></b></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify">In April 2014, the FASB issued ASU 2014-08, <i> Presentation of Financial Statements (Topic 205) and Property, Plant, and Equipment (Topic 360): Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity.</i> The update changes the requirements for reporting discontinued operations in Subtopic 205-20. A discontinued operation may include a component of an entity or a group of components of an entity, or a business. A disposal of a component of an entity or a group of components of an entity is required to be reported in discontinued operations if the disposal represents a strategic shift that has (or will have) a major effect on an entity’s operations and financial results. Examples include a disposal of a major geographic area, a major line of business or a major equity method investment. Additionally, the update requires expanded disclosures about discontinued operations that will provide financial statement users with more information about the assets, liabilities, income and expenses of discontinued operations. This update is effective prospectively for reporting periods beginning after December 15, 2014 and early adoption is permitted. The Company is currently evaluating the impact adoption will have on its financial statements.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify">In May 2014, the FASB issued ASU 2014-09, <i> Revenue from Contracts with Customers (Topic 606)</i> . The core principle of this ASU is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. This ASU provides for one of two methods of transition: retrospective application to each prior period presented; or, recognition of the cumulative effect of retrospective application of the new standard in the period of initial application. This ASU is effective for fiscal years and interim periods beginning after December 15, 2016 and early application is not permitted. Management currently believes the adoption this ASU will not have a material impact on the Company’s operating results, financial position or cash flows.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify">In June 2014, the FASB issued ASU No. 2014-12, <i> Compensation Stock Compensation (Topic 718): Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period</i> . The issue is the result of a consensus of the FASB Emerging Issues Task Force (EITF). The amendments in this ASU require that a performance target that affects vesting, and that could be achieved after the requisite service period, be treated as a performance condition. The amendments in this ASU are effective for annual periods and interim periods within those annual periods beginning after December 15, 2015 and can be either applied prospectively or retrospectively. Earlier adoption is permitted. Management currently believes the adoption this ASU will not have a material impact on the Company’s operating results, financial position or cash flows.</div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2013Q2	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	132000	USD
CY2013Q3	us-gaap	Area Of Land AreaOfLand	30000	sqmi
CY2013Q3	us-gaap	Restructuring Reserve Current RestructuringReserveCurrent	503000	USD
CY2013Q3	us-gaap	Restructuring Reserve Noncurrent RestructuringReserveNoncurrent	291000	USD
	dei	Document Type DocumentType	10-Q
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Period End Date DocumentPeriodEndDate	2014-09-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2014
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Entity Registrant Name EntityRegistrantName	ENZON PHARMACEUTICALS INC
	dei	Entity Central Index Key EntityCentralIndexKey	0000727510
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company
	dei	Trading Symbol TradingSymbol	ENZN
CY2014Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	44142340	shares
CY2013Q3	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	186000	USD
CY2013Q3	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	55000	USD
CY2013Q3	us-gaap	Share Based Compensation ShareBasedCompensation	300000	USD
	enzn	Reversed Share Based Compensation ReversedShareBasedCompensation	50000	USD
CY2013Q2	enzn	Payable For Restructuring PayableForRestructuring	95000	USD
CY2014Q3	enzn	Milestone Payment MilestonePayment	450000	USD

Files In Submission

Name	View Source	Status
0001144204-14-065728-index-headers.html	Edgar Link	pending
0001144204-14-065728-index.html	Edgar Link	pending
0001144204-14-065728.txt	Edgar Link	pending
0001144204-14-065728-xbrl.zip	Edgar Link	pending
enzn-20140930.xml	Edgar Link	completed
enzn-20140930.xsd	Edgar Link	pending
enzn-20140930_cal.xml	Edgar Link	unprocessable
enzn-20140930_def.xml	Edgar Link	unprocessable
enzn-20140930_lab.xml	Edgar Link	unprocessable
enzn-20140930_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
v392555_10q.htm	Edgar Link	pending
v392555_ex31-1.htm	Edgar Link	pending
v392555_ex31-2.htm	Edgar Link	pending
v392555_ex32-1.htm	Edgar Link	pending
v392555_ex32-2.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ENZN
Enzon Pharmaceuticals Inc Stock $enzn

2014 Q4 Form 10-Q Financial Statement

#000114420414065728 Filed on November 06, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ENZN Enzon Pharmaceuticals Inc Stock $enzn

2014 Q4 Form 10-Q Financial Statement

#000114420414065728 Filed on November 06, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ENZN
Enzon Pharmaceuticals Inc Stock $enzn